Business
Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada
Government of Canada exercises option to purchase an additional 4.5 million doses of Moderna's Omicron-containing bivalent vaccine booster
About this update from Moderna, Inc.
[{"type":"text","content":"Government of Canada exercises option to purchase an additional 4.5 million doses of Moderna's Omicron-containing bivalent vaccine booster candidatesCAMBRIDGE, MA / ACCESSWIRE / August 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Government of Canada has exercised its option to purchase an additional 4.5 million doses of an Omicron-containing bivalent vaccine booster candidate from the Company, in addition to moving forward the scheduled delivery of 1.5 million doses of the bivalent vaccine candidate from 2023 to 2022.Moderna and the Government of Canada have also agreed to convert six million doses of the Company's COVID-19 vaccine (Spikevax, mRNA-1273) to an Omicron-containing bivalent vaccine. The agreement is subject to regulatory approval of the Omicron-containing bivalent vaccine booster candidate by Health Canada, with doses scheduled for delivery in 2022.\"We thank the Government of Canada for their trust in our mRNA technology and our next-generation bivalent COVID-19 vaccine platform,\" said Stéphane Bancel, Moderna's Chief Executive Officer. \"As we have seen throughout this pandemic, the Government of Canada continues to take important steps in preparing for the winter season and protecting its people against Omicron.\"About ModernaIn over 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both ground-breaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowe...